ESLA
Estrella Immunopharma, Inc. NASDAQ$1.53
Mkt Cap $65.3M
52w Low $0.78
31.6% of range
52w High $3.15
50d MA $1.35
200d MA $1.40
P/E (TTM)
-4.7x
EV/EBITDA
-4.3x
P/B
—
Debt/Equity
0.0x
ROE
126.0%
P/FCF
-32.2x
RSI (14)
—
ATR (14)
—
Beta
0.58
50d MA
$1.35
200d MA
$1.40
Avg Volume
205.7K
About
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative part…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | AMC | -0.18 | -0.02 | +91.0% | 1.08 | +0.9% | +1.9% | -3.7% | -5.6% | -9.7% | -9.2% | +74.1% | — |
| Nov 12, 2025 | AMC | -0.19 | -0.13 | +30.3% | 2.10 | +3.3% | +4.8% | +8.1% | -11.4% | -13.3% | -16.7% | -17.6% | — |
| Aug 11, 2025 | AMC | -0.07 | -0.15 | -114.3% | 0.86 | -1.7% | +0.0% | -1.8% | -0.5% | +5.2% | +6.3% | +21.4% | — |
| May 14, 2025 | AMC | -0.11 | -0.06 | +45.5% | 0.99 | -0.3% | -5.0% | -3.1% | -1.0% | -1.0% | +2.0% | -3.0% | — |
| Feb 15, 2025 | AMC | -0.12 | -0.03 | +76.2% | — | — | — | — | — | — | — | — | — |
| Nov 14, 2024 | AMC | — | -0.09 | — | 0.84 | -6.0% | +6.0% | +5.9% | +1.3% | +9.6% | +6.0% | +51.2% | — |
| Sep 27, 2024 | AMC | — | -0.13 | — | 1.19 | -2.5% | -2.5% | +7.6% | +4.2% | -6.7% | -3.4% | -26.1% | — |
| May 14, 2024 | AMC | — | -0.01 | — | 1.05 | +7.6% | +2.9% | +0.0% | -3.8% | +0.0% | +0.0% | -9.5% | — |
| Feb 14, 2024 | AMC | — | -0.03 | — | 1.08 | +4.6% | +0.9% | +1.9% | -1.9% | -3.7% | -6.5% | +2.8% | — |
| Sep 30, 2023 | AMC | — | -1.78 | — | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 9 | D. Boral Capital | Maintains | Buy → Buy | — | $1.45 | $1.34 | -7.6% | -1.4% | -4.8% | -10.3% | -15.2% | -13.1% |
| Jan 28 | D. Boral Capital | Maintains | Buy → Buy | — | $1.07 | $1.09 | +1.9% | -0.9% | +0.9% | +4.7% | +1.9% | +9.3% |
| Nov 3 | D. Boral Capital | Maintains | Buy → Buy | — | $2.42 | $2.43 | +0.4% | +26.0% | -5.4% | +5.8% | +14.0% | +21.1% |
| Aug 12 | D. Boral Capital | Maintains | Buy → Buy | — | $0.86 | $0.85 | -1.7% | +0.0% | -1.8% | -0.5% | +5.2% | +6.3% |
| Jun 3 | D. Boral Capital | Maintains | Buy → Buy | — | $0.97 | $1.10 | +13.4% | -14.0% | +2.1% | +9.3% | +10.3% | +1.9% |
| May 29 | D. Boral Capital | Maintains | Buy → Buy | — | $0.97 | $0.97 | +0.0% | +5.2% | +4.1% | +0.0% | -14.0% | +2.1% |
| Feb 21 | D. Boral Capital | Maintains | Buy → Buy | — | $1.49 | $1.69 | +13.4% | -0.7% | -11.4% | -22.1% | -26.2% | -35.6% |
Data updated apr 25, 2026 7:41am
· Source: massive.com